Gilead Sciences (NASDAQ:GILD) unit Kite has submitted a marketing application to the FDA seeking approval for CAR T therapy KTE-X19 for the treatment of adults with relapsed/refractory mantle cell lymphoma, a type of slow-growing NHL.
The company plans to file an application in Europe next quarter.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.